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Abstract: Influenza A and B viruses are highly contagious respiratory pathogens with a considerable
medical and socioeconomical burden and known pandemic potential. Current influenza vaccines require
annual updating and provide only partial protection in some risk groups. Due to the global spread of
viruses with resistance to the M2 proton channel inhibitor amantadine or the neuraminidase inhibitor
oseltamivir, novel antiviral agents with an original mode of action are urgently needed. We here focus on
emerging options to interfere with the influenza virus entry process, which consists of the following steps:
attachment of the viral hemagglutinin to the sialylated host cell receptors, endocytosis, M2-mediated
uncoating, low pH-induced membrane fusion, and, finally, import of the viral ribonucleoprotein into the
nucleus. We review the current functional and structural insights in the viral and cellular components of
this entry process, and the diverse antiviral strategies that are being explored. This encompasses small
molecule inhibitors as well as macromolecules such as therapeutic antibodies. There is optimism that
at least some of these innovative concepts to block influenza virus entry will proceed from the proof of
concept to amore advanced stage. Special attention is therefore given to the challenging issues of influenza
virus (sub)type-dependent activity or potential drug resistance. C© 2013 Wiley Periodicals, Inc. Med. Res. Rev.,
00, No. 0, 1–39, 2013
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1. INTRODUCTION
Human influenza A and B viruses cause significant morbidity and mortality, particularly in in-
fants and elderly people, or those suffering from preexisting pathology or immunodeficiency.1,2
The United States Centers for Disease Control and Prevention estimated that, from 1976 to
2000, seasonal influenza epidemics were responsible for >200,000 annual hospitalizations and
an annual average of >30,000 influenza-associated deaths in the USA.3 Approximately 90% of
the influenza-associated deaths occur among adults aged ≥65 years.4
To evade the immune response, the circulating influenza H3N2, H1N1, and B viruses
continuously change their antigens, and this explains why current influenza vaccines require
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Figure 1. Overview of the influenza virus entry and replication process. In the inset on the right, the different
virion components are specified. (a) After binding of the viral HA to sialylated glycans on the host cell surface,
the virus is internalized by endocytosis. (b) Acidification of the endosome leads to activation of the M2 proton
channel and virion acidification, resulting in virus uncoating (i.e., dissociation of the vRNPs from the M1 capsid
protein). The low pH inside the endosome also triggers a conformational change in the HA, leading to fusion
of the viral and endosomal membranes. After vRNP release in the cytoplasm and dissociation of residual M1,
nuclear localization signals in NP direct the transport of the vRNPs into the nucleus. (c) In the nucleus, the viral
polymerase starts mRNA synthesis by cleaving off 5′-capped RNA fragments from host cell pre-mRNAs. Then,
viral mRNA transcription is initiated from the 3′ end of the cleaved RNA cap. (d) Viral mRNAs are transported to
the cytoplasm for translation into viral proteins. HA, M2, and NA are processed in the endoplasmic reticulum and
the Golgi apparatus, and subsequently transported to the cell membrane. (e) Besides viral mRNA synthesis,
the viral polymerase performs the unprimed replication of vRNAs. The vRNAs are first transcribed into positive-
stranded cRNAs, which then function as the template for the synthesis of new vRNAs. During their synthesis,
vRNAs and cRNAs are encapsidated by NPs. Export of the newly formed vRNPs into the cytoplasm is mediated
by an M1-NS2 complex that is bound to the vRNPs. (f) As they reach the cell membrane, the vRNPs associate
with viral glycoproteins at the plasma membrane from which new virions bud off. Finally, the NA cleaves the sialic
acid termini on viral and cell membrane glycoproteins, thereby releasing the progeny virions from the host cell.
annual updating. These vaccines provide inadequate protection in some target populations
(particularly the elderly).5 Besides, there is concern that thewidely spread and highly pathogenic
avian H5N1 influenza virus may acquire human transmissibility and become a potentially
disastrous pandemic virus. The human case-fatality rate of this avian H5N1 is reported to be
59%,6 although some investigators have raised the possibility that subclinical cases of H5N1
infections in humans may remain unnoticed.7 For comparison, the case-fatality rate of the 1918
influenza virus was estimated >2.5%.8
As shown in Figure 1, the influenza virus replication cycle contains several steps amenable
to antiviral intervention. This review focuses on the viral entry pathway, which, given the acute
onset of influenza virus infection and the inflammation associated with it, is a particularly
attractive process to interfere with. We describe the current insights into the structure and
functions of the viral and cellular components involved in this entry process, and the antiviral
strategies that are being explored (an overview of the described compounds is given in Table I).
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For antiviral approaches affecting other stages in the viral life cycle, the reader is referred to
other recent review articles.9–12
2. CURRENTLY AVAILABLE ANTI-INFLUENZA VIRUS DRUGS
Effective antiviral drugs to prevent or treat influenza infections should at all times be available.
Today, two classes of anti-influenza virus drugs exist: the M2 proton channel blockers (i.e.,
the adamantane compounds, amantadine and rimantadine), and the neuraminidase inhibitors
(NAIs) (oseltamivir and zanamivir).13 The first two compounds have limited utility, since they
are associated with neurological side effects, have no activity against influenza B virus, and the
vast majority of circulating strains are adamantane-resistant.13 A detailed description of their
mode of action and resistance mechanisms will be given below. The obviously superior class
of anti-influenza virus drugs are the NAIs oseltamivir and zanamivir that are active against
all influenza A and B viruses. These structural analogues of sialic acid bind to the catalytic
pocket of the viral NA and inhibit its function in releasing the newly produced virus from the
host cells.14,15 There is a critical difference in the NA binding mode of oseltamivir compared
to that of zanamivir, which explains their significantly different resistance profile. Due to its
larger hydrophobic side chain, oseltamivir requires rotation of the noncatalytic Glu276 residue
within NA to create a binding space for oseltamivir.16 By contrast, the smaller size of zanamivir
enables direct binding of this compound to NA. In a mutant N1 NA containing a His to Tyr
substitution at position 274, this rotation can no longer occur, rendering the NA resistant to
oseltamivir binding. During the 2008–2009 season, oseltamivir-resistant H1N1 viruses were
isolated all over the globe, even from untreated patients.17,18 In a Japanese study in 2004,
nine out of 50 children treated with oseltamivir carried oseltamivir-resistant H3N2 viruses.19
Fortunately, oseltamivir-resistant viruses are still sensitive to zanamivir, for which resistance
has only scarcely been reported.20,21 On the other hand, the patient-unfriendly administration
route for zanamivir (i.e., by powder inhalation device) explains why oseltamivir (which is given
by oral capsules) is generally preferred in the clinical setting. Inhalation of zanamivir is a priori
excluded in patients suffering from severe influenza symptoms with acute respiratory distress,
such as patients infected with the highly pathogenic avian H5N1 virus, or severe cases of the
2009 pandemic H1N1 virus. To address this issue, an intravenous formulation of zanamivir is
under consideration.22,23 Besides, new NAIs are being developed. Peramivir, which has to be
administered intravenously, has been licensed in Japan and South Korea, while, in the United
States, its use was temporarily allowed during the 2009 H1N1 pandemic.24 Unfortunately, the
widespread oseltamivir-resistant H1N1 His274Tyr mutants show intermediate cross-resistance
to peramivir.25 Another NAI, laninamivir (CS-8958), was approved in Japan in 2010 and is
currently in Phase III trials in the United States.26,27 This promising compound requires only
one single intranasal administration (based on its long half-life), and has a similar NA binding
mode and favorable resistance profile as zanamivir.28 Finally, novel NAIs with a sialic acid-
related or unrelated structure have been developed by rational design, but are still in the early
experimental stage.29–31
To face the emerging resistance to NAIs (in particular, oseltamivir), entirely novel anti-
influenza virus drugs are urgently needed. The two products that are most advanced in clinical
development are the nucleobase analogue T-705 (favipiravir) and the receptor destroying pro-
tein DAS181. For T-705, Phase III trials in the United States are pending. Its active ribose-
triphosphate metabolite is recognized by the influenza virus polymerase, causing competitive
inhibition of viral RNA synthesis and/or lethal viral mutagenesis.32 T-705 has broad anti-RNA
virus activity beyond influenza virus and is presumed (based on cell culture data) to have a
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high barrier for viral resistance.33 The second agent, DAS181, is currently in Phase II trials.
This recombinant protein is a sialidase that cleaves the influenza virus receptors in the airway
epithelia. More details on DAS181 are provided in Section 3.
3. INHIBITORS OF THE HEMAGGLUTININ-RECEPTOR INTERACTION
A. Structure of the Viral Hemagglutinin
Within the influenza virus particle, the single-stranded, negative-oriented RNA genome is
divided over eight viral ribonucleoprotein (vRNP) segments, which are protected by the capsid
shell formed by the M1 protein, further surrounded by the viral envelope. Two viral spike
proteins protrude from the virion: the hemagglutinin (HA) and NA, which have a leading role
in viral entry and release, respectively. The HA and NA glycoproteins are the main antigens
against which the host immune response is raised. In the case of influenza A virus, 17 HA
and 10 NA subtypes are known, which are all present in aquatic birds, the natural reservoir
for influenza A viruses.34 The only exception is H17, which was isolated only recently from
bats.35,36 The emergence of a new pandemic virus is explained by the reassortment of genome
segments, which occasionally occurs upon dual infection of an animal species (such as a pig)
that carries the avian- as well as the human-type influenza virus receptors.37
The influenza virus HA (Fig. 2A) is a homotrimeric type 1 membrane glycoprotein. Its
membrane-distal globular head domain contains the receptor binding site (RBS), whereas
the HA stem structure (which contains the fusion peptide) is responsible for intraendosomal
membrane fusion.34 In influenza virus-infected cells, HA is first synthesized as its precursor
proteinHA0, which assembles into a noncovalently linked homotrimer38 and is cleaved into two
polypeptides (HA1 and HA2 containing, in the case of H3, 328 and 221 amino acids, respec-
tively), which remain covalently attached by a disulfide bond.39 For most HAs, HA0 cleavage
occurs at a single arginine residue and is performed by a membrane-bound or secreted serine
protease that is restricted to bronchiolar epithelium, such as tryptase Clara, the human airway
trypsin-like protease or TMPRSS2.40,41 The HAs from highly pathogenic avian viruses contain
a series of basic residues at their cleavage site,42 allowing recognition by furin-like intracellular
proteases that are widely distributed in avian tissues, thus explaining their systemic spread and
high virulence.43 Inhibition of the cellular proteases performing HA0 cleavage is an original
antiviral strategy, and peptidomimetic furin inhibitors have proven to inhibit the replication of
an avian influenza virus in cell culture.44 After HA0 cleavage, minor rearrangements lead to
insertion of the fusion peptide (located at the N-terminus of HA2) into a negatively charged
cavity, thus priming the HA for pH-dependent fusion.40 Posttranslational modifications of HA
comprise the addition of acyl chains to the short cytoplasmic tail,45 and N-glycosylation at
several asparagine residues in the ectodomain.39 Besides masking the antigenic epitopes by
sterically hindering antibody recognition,46,47 the N-linked glycans also function in the correct
folding of HA in the endoplasmic reticulum,48,49 modulation of receptor binding,50 controlling
HA0 cleavage,51 and maintaining the HA in its metastable conformation required for fusion
activity.52 The N-glycans that are most conserved among various influenza HAs are located at
the N-terminus of HA0 (or after cleavage, HA1)48 and in the HA stem region.53
The 17 influenza HA subtypes are classified into two phylogenetic groups (Fig. 2B). The
H1 and H5 HAs belong to the same clade within group 1, whereas H3 HA belongs to group
2.35,54,55 Although this phylogenetic classification was primarily based onHAprotein sequence,
comparison of available HA crystal structures indicates that the regions involved in membrane
fusion show striking similarities on a group-specific basis.54
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Figure 2. Structure and classification of influenza A HAs. (A) Structure of the viral hemagglutinin, showing the
binding site for sialic acid (violet) in the globular head domain (blue ribbon structure), as well as the binding
pockets in the HA stem structure for fusion inhibitors reported to prevent the HA conformational change, that is,
the small-molecule inhibitor TBHQ (orange) and the broad-acting antibodies F10 (pink) and CR6261 (yellow).
Two HA subunits are represented by their combined molecular surface, while the third one is shown in a ribbon
diagram. [Reprinted by permission from Macmillan Publishers Ltd: Nature Structural & Molecular Biology Ref.
Das et al.10 C© (2010).] (B) Phylogenetic tree of influenza A HAs. Group 1 (cyan) can be subdivided into three
clades (H8, H9, and H12; H1, H2, H5, and H6; H11, H13, and H16). Group 2 (green) is subdivided in two
clades (H3, H4, and H14; H7, H10, and H15). The newly identified H17 is classified in the H1 clade of group
1.35 [Taken from Russell et al.,55 Copyright (2008) National Academy of Sciences, USA.] (C) Detail of the HA
RBS indicating the binding mode of the CDR-H3 loop (heavy-chain complementarity determining region 3) of
antibody CH65, which acts as a sialic acid mimic. The HA RBS is colored pink and the CDR-H3 loop is shown
in blue. The residues relevant for the antibody-HA interaction are labeled; some of these are conserved HA1
residues involved in sialic acid binding (Ser1361, Trp1531, and Leu1941). [Taken, with permission, from Whittle
et al.79] (D) Cartoon of the structural changes in HA during the HA-mediated membrane fusion process. [a] The
HA RBS binds to the sialylated cell receptor (in green). [b] The acidic pH in the endosome induces HA refolding,
which leads to the exposure of the fusion peptide (in red) and its insertion in the endosomal membrane. [c] As
a result of further conformational changes in HA, the viral and endosomal membranes are pulled together. [d]
Mixing of the outer membrane leaflets generates the prefusion stalk intermediate. The dashed lines separate the
inner and outer membrane leaflets. [Taken from Hamilton et al.,251 with permission]
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B. Species-Specific Virus Binding to Sialylated Glycan Receptors
In the first step of the infection cycle, the HA attaches, via the RBS in its globular head, to
sialylated glycoproteins or glycolipids on thehost epithelial cells.56 ThisHA-receptor interaction
is highly specific for sialylglycoconjugates and plays an essential part in the species recognition
of avian versus human influenza viruses.57 The HAs from human-adapted viruses, including
the pandemic viruses of the H1N1, H2N2, or H3N2 subtype, preferentially bind to cell-surface
glycans terminating in α2-6-linked sialyl-galactosyl residues [Neu5Ac(α2-6)Gal], whereas avian
influenza A viruses have a preference for α2-3-linked sialyl-galactosyl termini.58–62 The HAs
of influenza B viruses which, in nature, are only detected in humans and seals, show a binding
preference for α2-6-linked glycans.63–65 Thus, it is important to underline that the species
specificity of the HA–glycan interaction is not based on recognition of the terminal sialic acid
itself, but, rather, its linkage to the vicinal galactose and the sugars beyond galactose.66,67 A
correlation between glycan topology and species specificity was established from HA–glycan
cocrystal structures as well as glycan array data.58 With regard to the HA residues that are
directly involved in sialic acid binding, these are highly conserved across different HA subtypes.
These amino acids (Tyr981, Ser1361, Trp1531, His1831, Leu1941) [amino acid numbering based
on the H3 HA sequence; the suffixes 1 and 2 denote location in the HA1 and HA2 subunit,
respectively] lead to a fixed orientation of the sialic acid relative to the HA RBS.68
Although sialic acid is generally considered to be the primary attachment receptor, influenza
virus is able to bind and enter (though considerably less efficiently) into cells of which all surface
sialic acids, whether attached to glycolipids or glycoproteins, were removed by treatment with
exogenous Micromonospora viridifaciens sialidase.69 Hence, it has been proposed that, besides
sialic acid, other receptors may be involved in influenza virus entry, which can work either
independently or via a multistep process.69,70
Which specific amino acid residues in HA govern its avian versus human receptor pref-
erence, varies among the different HAs, and is still incompletely understood, although α2-6
tropism is generally linked to residues Asp1901 and Asp2251 in H1 and Leu2261 in H2 and H3
HAs.71 To cross the avian–human species barrier, acquisition of the human receptor binding
preference is not sufficient, since additional amino acid changes are required, particularly in
the influenza virus polymerase complex.71 In a recent study in which the avian H5N1 virus was
passed in ferrets, four mutations in the head domain of H5 HA, combined with the Glu627Lys
hallmark mutation in the PB2 subunit of the polymerase complex, were able to lead to airborne
transmission of this virus in ferrets.72 A similar study with a reassortant virus carrying the HA
of avian H5N1 also concluded that its avian-to-mammalian adaptation requires a combination
of HAmutations to not only switch its receptor preference from α2-3 to α2-6, but also increase
the stability of the HA protein.73
C. Antiviral Strategies to Interfere with HA-Receptor Binding
When considering the HA-receptor binding as an antiviral target, the multivalent nature of
this interaction may present as a challenge. This binding is highly dynamic and involves an
ensemble of sialylated glycans making contact with multiple HA trimers.74 In this manner, the
avidity effects of the multivalent interaction compensate for the intrinsically low glycan binding
affinity for a single binding site on HA [with a dissociation constant (Kd) in the millimolar
range].75
Thus, to develop inhibitors that block the receptor binding of HA, at least three factors
need to be taken into account: large sequence variation amongHA subtypes and antigenic drift
of HA; avian versus human-specific receptor use; and multivalent nature of the HA-receptor
interaction. An ideal inhibitor would be species- and HA subtype-independent. There are
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three conceivable strategies for inhibiting attachment of influenza virus to its target cell: (i) an
antiviral compound binding to theHARBS; (ii) an inhibitor blocking the sialic acid-containing
receptors on the epithelial cell membrane; or (iii) a receptor-destroying agent.
1. HA-Binding Agents
Virus-neutralizing antibodies
The first and natural types of binding inhibitors are the virus-neutralizing antibodies raised dur-
ing the course of an influenza virus infection. These neutralizing antibodies are predominantly
directed toward the surface of the membrane-distal globular head domain of HA.76 During
the 1918 pandemic, some patients were treated with human blood products from recovering
influenza patients.77 Eight controlled studies reported between 1918 and 1925 were recently
reviewed, and it was concluded that the overall case-fatality rate was reduced from 37% among
control patients to 16% among treated patients. Treatment was most effective when initiated
early (i.e., less than 4 days after pneumonia became apparent).77 These historical data demon-
strate that passive immunization with anti-HA antibodies can be considered in case a pandemic
occurs. Obviously, safety considerations about the use of patient-derived materials need to be
addressed. An elegant method for the isolation of human antibodies was reported by Simmons
et al.,78 who prepared H5N1 neutralizing monoclonal antibodies from the memory B-cells of
patients recovered from an H5N1 infection. Two monoclonal antibodies were effective in a
mouse influenza model when administered no later than 72 hr after infection.78 An attractive
new concept is the development of monoclonal antibodies that bind to the conserved RBS
of HA and, hence, are endowed with heterosubtypic HA neutralizing activity. A first human
monoclonal antibody directed against H1 HA, encoded CH65, was derived from plasma cells
of a person immunized with the 2007 trivalent influenza vaccine. Cocrystallization of its Fab
fragment with H1 HA revealed that this antibody acts as a sialic acid mimic since the tip of
its heavy-chain complementarity determining region 3 (HCDR3) inserts in the RBS of H1 HA
(Fig. 2C).79 Since CH65 was shown to neutralize 31 out of 36 H1N1 isolates covering a period
of more than 30 years, and to interact with the conserved RBS itself, resistance selection by
CH65 may be expected to be rare, unless associated with reduced viral fitness.79,80 It should
however be noted that the RBS of HA is smaller than the interaction site of an antibody81
and, therefore, CH65 forms additional interactions with RBS surrounding residues that are less
conserved among the different HAs. The more broadly acting monoclonal antibody C05 binds
to H1, H2, H3, H9, and H12 HAs and was isolated from a phage-display library constructed
from bonemarrow donated after seasonal influenza infection. Cocrystallization studies demon-
strated that the HCDR3 part of C05 forms a loop that inserts into the conserved RBS of HA,
while its HCDR1 region makes only minimal contact with RBS surrounding and more variable
residues.82 A third cross-reactive monoclonal antibody, S139/1, neutralizes H1, H2, H3, H13,
and H16 virus strains.83 The HCDR2 region of S139/1 was shown to form multiple hydropho-
bic interactions within the RBS of H3 HA. The rather low affinity of this binding interaction
is compensated in the bivalent IgG molecule, and this avidity effect is required to broaden the
neutralizing activity of S139/1 to strains of the H1, H2, H13, and H16 subtypes.84 Regard-
ing influenza B viruses, the human monoclonal antibodies 3A2 and 10C4, reactive against B
viruses of the Yamagata lineage, recognize the 190-helix (residues 190–198 in HA1) near the
RBS.85 The humanmonoclonal antibodiesCR8033 andCR8071were shown to neutralize both
Yamagata and Victoria lineage B viruses and protect mice after challenge with a lethal dose of
influenza virus.86 Although the therapeutic use of an anti-influenza antibody may appear com-
plicated, some parallel can be seen with the palivizumab antibody that is already in use for the
prophylaxis of another respiratory virus, that is, respiratory syncytial virus (RSV).87 An inno-
vative strategy to improve the pharmacokinetics and reduce the production cost of therapeutic
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antibodies consists of single-domain antibody fragments (also referred to as Nanobodies) de-
rived from camelid immunoglobulins.88 A Nanobody directed to the globular head of H5 HA
was shown to be effective inH5N1-infectedmice. The activity of themonovalentNanobodywas
increased by a factor 60 when using a bivalent format, consisting of two paratope containing
domains connected by a flexible linker.89
Lectins
Another type of immune proteins capable of catching viruses is the collagenous C-type lectins
(referred to as collectins) such as the lung surfactant proteins. The role of surfactant protein D
(SP-D) in the innate immune response to influenza virus is explained by its capacity to cause
virus particle aggregation, thereby preventing virus attachment to the host cells.90 Besides,
SP-D has various immunological effects that account for its ability to limit lung inflammation
by respiratory pathogens.91 Regarding potential antiviral use, design of modified forms of the
porcine SP-D lectin (which has higher anti-influenza virus activity than its human counterpart)
is aided by the growing insight into how its carbohydrate recognition domain (CRD) pre-
cisely interacts with the high-mannose glycans attached near the RBS of HA.92,93 In addition,
N-linked sialoglycans attached to the CRD of SP-D are considered important, since they may
cause additional interactions between the SP-D and the HA RBS and enhance the antiviral
effect.90 A similar action principle, that is, binding to high-mannose carbohydrates on the viral
HA, accounts for the anti-influenza virus activity of the bovine serum lectinCL-43.94 Likewise,
cyanovirin-N, a lectin isolated from Escherichia coli, recognizes high-mannose oligosaccharide
structures on diverse viral glycoproteins, explaining its broad activity against unrelated viruses
such as influenza virus and HIV.95 Cyanovirin-N was shown to inhibit influenza virus repli-
cation in cell culture as well as mouse and ferret infection models.96,97 Although SP-D and
cyanovirin-N manifest broad anti-influenza A and B virus activity, some virus strains (such
as the A/PR/8/34 H1N1 strain) are known to be insensitive, due to the lack of particular
Asn-linked oligosaccharides on the head of their HA.98 The location and number of glycans
attached to the head of HA is quite variable, since acquisition of epitope shielding oligosac-
charides is part of the viral immune escape.46 In contrast, the glycans attached to the HA
stem have a structural function in protein refolding, and the corresponding glycosylation sites
are therefore more conserved.52,53 This implies that antiviral use of lectin compounds directed
toward HA head glycans might lead to escape mutants devoid of specific glycans, although the
newly exposed antigenic sites might also render the mutated virus susceptible to immunological
control.99
Sialyl-containing macromolecules and sialomimetics
An alternative approach to block the HA RBS makes use of receptor mimics, such as
sialyl-containing macromolecules. The gangliosides sialylparagloboside (SPG) and GM3
(Neu5Acα2-3Galβ1-4Glcβ1-1′ceramide) were proven to bind to HA and inhibit the virus-
induced cytopathic effect,100–102 and their antiviral activity correlated with their HA binding
affinities.101 The hydrophobic ceramide moiety of SPG and GM3 was found essential, since the
uncoupled trisaccharides 3′-sialyllactosamine and 3′-sialyllactose (which constitute the termini
of SPG and GM3, respectively) produced no effect. Micelle formation of these gangliosides in
aqueous solution likely causes protrusion of their sialic acid parts toward the outside of the
micelles, resulting in high sialic acid density and, hence, a multivalent binding interaction with
HA.101
In a recent report, Hendricks et al. described that liposomes bearing sialylneolacto-N-
tetraose c (LSTc) can form multivalent interactions with influenza virus.103 In contrast to
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Figure 3. Chemical structures of diverse antiviral agents reported to inhibit the entry of, among others, influenza
viruses. The sulfated sialyl lipid NMSO3 may act upon influenza virus binding107; glycyrrhizin may reduce
membrane fluidity125,126; and dextran sulfate184 and arbidol197 probably interfere with the low pH-induced
fusion process (see the text for all details).
monovalent LSTc, these decoy liposomes are able to competitively bind influenza virus in a
hemagglutination inhibition assay, and suppress influenza virus replication in cell culture and
mouse models.
Pentadecapeptides binding toH1andH3HAswere obtained fromphage-displayed random
peptide libraries by serially repeated affinity selection.A docking simulation indicated that these
peptides act as sialomimetics. Some showed inhibitory activity against H1 and H3 influenza
viruses in cell culture.104 Jeon et al. used a peptide with a sequence derived from the globular
head region of HA to screen a DNA library for HA-binding aptamers. The selected aptamer,
A22, was proven to block the RBS of HA and inhibit influenza A viruses in vitro (i.e., cell
culture) and in vivo (i.e., animal studies).105
Another macromolecule, the sulfated sialyl lipidNMSO3 (Fig. 3) showed antiviral activity
against influenza H3N2, but not against B viruses.106 We recently found that NMSO3 inhibits
influenza virus binding to cells at 4◦C.107 Although NMSO3 has a strong negative charge
and, hence, a direct interaction of NMSO3 with the sialic acid binding residues of the HA
RBS can be anticipated, the precise mode of action of this antiviral compound remains to be
determined. NMSO3 has broad activity against diverse viruses (in cell culture as well as animal
models)106,108 and presents as a relevant antiviral lead compound.
2. Receptor-Binding Agents
The opposite strategy to block binding of influenza virus to its cell receptor, is the devel-
opment of sialic acid binding compounds. The HA-binding and Neu5Acα2-3Gal-containing
ganglioside GM3 was used to select potential inhibitors from a phage-displayed random pep-
tide library.109 Two pentadecapeptides, c01 (GWWYKGRARPVSAVA) and c03 (RAVWRHS-
VATPSHSV), were picked out and acylated to a C18 group, in order to form a molecular as-
sembly and promote multivalent binding. Both C18-peptides provided inhibition of influenza
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virus infection in cell culture. Their anti-influenza virus activity was comparable to that of the
wheat-germ agglutinin lectin,109 which is known to interact with sialoglycoconjugates.110
3. Receptor Destroying Agents
Finally, a third strategy for inhibition of virus binding is destruction of the sialylated glycan
receptors. Years ago, it was observed that cells are less susceptible to influenza virus infection
after enzymatic removal of sialic acid from the cell surface.111 The new anti-influenza virus agent
DAS181 is a recombinant fusion protein, consisting of a sialidase catalytic domain derived from
Actinomyces viscosus and an epithelium-anchoring domain. DAS181 efficiently removes α2-3-
and α2-6-linked sialic acids and displays broad activity against influenza A and B viruses as
well as parainfluenza viruses.112,113 Since DAS181 acts on the host cell rather than the virus,
it is assumed to have a reduced potential for generating drug resistance. After more than 30
passages in the presence ofDAS181, influenza virusmutants were selected with low tomoderate
resistance to the compound (i.e., three- to 18-fold increase in antiviral EC50 value). The resistant
viruses showed an attenuated phenotype compared to the wild-type virus, yet unchanged
virulence in mice. When further passaged in the absence of compound, the viruses quickly
regained the wild-type sensitivity. Sequencing revealed that the resistant mutants contained
substitutions in the HA near its RBS, as well as in the NA, leading to altered HA and NA
functionality.114 The concern that desialylation of the airway epithelium might unmask certain
cryptic receptors and increase the susceptibility to Streptococcus pneumonia, was contradicted
by mouse experiments showing that DAS181 treatment does not lead to an increased incidence
of secondary pneumonia.115 DAS181 requires topical delivery as an inhalant. It is currently
in Phase II clinical trials (at once daily dosing of 10 mg during 3 days) for the treatment and
prophylaxis of influenza-like illness.116
4. INHIBITION OF ENDOCYTIC UPTAKE OR VIRUS TRAFFICKING
A. Different Endocytic Routes Exploited by Influenza Virus
After binding to the sialylated glycans on the cell surface, influenza virions are internalized by
endocytosis. In general, viruses can be internalized by clathrin-mediated endocytosis (CME);
caveolin-mediated endocytosis; macropinocytosis; or other less characterized mechanisms.117
Early electron microscopic analysis of influenza virus-infected cells showed the presence
of virions in clathrin-coated pits and vesicles, providing direct evidence that influenza virus
can enter the cell by CME. However, since virions were also found in smooth pits, the virus
is able to follow an alternative clathrin-independent pathway.118 Further support came from
investigations in which dominant negative forms of cellular endocytic regulators were ex-
pressed, or by using pharmacological inhibitors, that is, the CME inhibitor chlorpromazine,
the cholesterol-depleting agents nystatin or methyl-β-cyclodextrin; or genistein, an inhibitor of
caveola formation.119
Additional evidence that influenza virus exploits CME and a clathrin- and caveolin-
independent route in parallel, was provided by real-time imaging. Both routes appear to be
equally efficient in supporting the infection once the virus is internalized.120 Only recently,
the clathrin- and caveolae-independent influenza virus uptake was shown to have the char-
acteristics of macropinocytosis.121 Influenza virus entry was completely inhibited when cells
were simultaneously treated with dynasore and the amiloride derivative EIPA, which inhibit
dynamin-dependent CME and macropinocytosis, respectively.
The sialic acid attachment sites for influenza virus possess no host cell signaling capacity
and, hence, additional postattachment factors may be required for efficient viral entry.122 Since
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the virus fails to enter Lec1 cells, a mutant CHO cell line that is totally deficient in N-terminal
glycosylation, it was suggested that N-linked glycoproteins may be required for efficient endo-
cytosis of the virus.122 Besides, binding of influenza A virus to cells was found to induce lipid
raft rearrangement and activation of signaling molecules, such as the epidermal growth factor
receptor (EGFR) or other receptor tyrosine kinases. Also, it was observed that the activated
EGFR kinase is involved in promoting the initial virus uptake, and that virus internalization
was considerably reduced in the presence of genistein, a broad inhibitor of receptor tyrosine
kinases.123
Thus, the precise mechanisms for endocytic uptake of influenza virus are still not fully
understood. Whether any of these insights may be translated into a relevant antiviral concept
is unsure. Influenza virus appears to exploit endocytic routes and signaling platforms that
are intimately linked to normal cell functioning and thus not readily amenable to selective
antiviral intervention. For instance, the above-mentioned pharmacological agents, which were
very useful to demonstrate the role of CME or macropinocytosis, only affect the viral uptake
at subtoxic concentrations.
B. Antiviral Strategies to Interfere with Endocytic Uptake and Virus Trafficking
Onepotential approach is the use ofmembranefluiditymodulators,which restrict themovement
ofmembranemolecules. The neutral glycolipid fattiviracin (FV-8; isolated fromStreptomycetes)
interferes with cell–cell fusion inHIV-infected cells and was also reported to have anti-influenza
virus activity.124 Interference with cell membrane fluidity may also be the principal mode of ac-
tion of glycyrrhizin (Fig. 3), the main active constituent of licorice root. Glycyrrhizin has broad
antiviral activity against diverse enveloped viruses, including influenza virus, herpes simplex
virus (HSV), varicella-zoster virus (VZV), vaccinia virus, vesicular stomatitis virus, measles
virus, HIV-1, and the SARS coronavirus.125,126 Its anti-influenza virus activity was already
demonstrated in 1983.127 More recently, a flow cytometric internalization assay was used to
show that glycyrrhizin inhibits the endocytic uptake of influenza virus.126 Glycyrrhizin was
further proven to decrease the fluidity of the cell membrane, an effect that was attributed to its
cholesterol-related chemical structure125 (Fig. 3). Besides its antiviral effect, glycyrrhizin dis-
plays anti-inflammatory and immunomodulatory effects.128 These combined pharmacological
effects may be advantageous in the treatment of virus infections with a strong inflammatory
component, such as the severe airway inflammation (cytokine storm) caused by the avianH5N1
virus.128 In Japan, glycyrrhizin is already in clinical use since many years, and based on this the
compound is considered to have favorable safety with no serious side effects.125,126
Another broad-spectrum antiviral agent interfering with membrane fusion is the aryl
methyldiene rhodamine derivative LJ001. This compound displays activity against a wide
range of unrelated enveloped viruses, including influenza A virus, HIV-1, yellow fever virus,
hepatitis C virus (HCV), vesicular stomatitis virus, and vaccinia virus.129 Time-of-addition
experiments demonstrated that LJ001 acts upon virus entry, since inhibition was only achieved
when the compound was added before or during infection. LJ001 was shown to intercalate
into viral as well as cellular membranes. Its potent antiviral activity and low cytotoxicity was
explained by the capacity of the host cell for active and rapid biogenic repair, while disruption
of the virion envelope is irreversible.
Lipoglycopeptides are lipophilic derivatives of glycopeptide antibiotics such as the widely
used antibiotic vancomycin. Some lipoglycopeptides are not only endowed with increased
antibacterial activity, but also display activity against diverse viruses such as HIV, herpes
viruses, or flaviviruses.130 Regarding influenza virus, we recently described the structure–
activity relationship of a series of aglycoristocetin derivatives containing an aryl-substituted
cyclobutenedione.131 The lead compound SA-19, which carries a phenylbenzyl substituent,
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displayed strong and consistent activity against all influenza A and B viruses tested.107 No
resistance to SA-19 was observed after 15 virus passages in cell culture. This compound was
shown to cause intracytoplasmic trapping of influenza virus prior to its nuclear entry, presum-
ably by disturbing the endocytic uptake of the virus at the site of the plasma membrane. It
would be relevant to see whether kistamicin A and B, two ristocetin-related glycopeptides that
were reported to have anti-influenza virus activity several years ago,132 display a similar mode
of action as SA-19. This is somewhat suggested by the fact that the antiviral activity is higher
for kistamicin B, which contains a lipophilic substituent analogous to that of SA-19.
An alternative strategy would be to interfere with endosome acidification. Upon internal-
ization and entry into early endosomes, influenza viruses undergo an initial acidification step
to pH ∼ 6. They then traffic to late endosomes, where further acidification to pH ∼ 5 provides
the trigger for fusion of the endosomal and viral membranes.133 Acidification of the endosomes
is accomplished by the cellular vacuolar proton ATPase (V-ATPase), which is potently and
selectively inhibited by the macrolide antibiotics bafilomycin A1 and concanamycin A. Both
compounds block influenza virus entry when added within the first 10 min after infection.134 A
different type of V-ATPase inhibitor, the natural compound diphyllin, produced surprisingly
potent and selective inhibition of influenza virus replication in cell culture.135 Likewise, lysoso-
motropic weak bases such as ammonium chloride and chloroquine inhibit influenza virus entry
by elevating the endosomal pH.118,136 Chloroquine shows in vitro anti-influenza virus activity
at concentrations that can, based on data from its use for malaria prophylaxis, be reached in
humans.137 However, a double-blind, placebo-controlled efficacy trial concluded that chloro-
quine is unable to prevent influenza virus infection,138 and this agrees with its failure to prevent
influenza virus infection in mouse and ferret models.139 Possibly, the chloroquine dose used in
the clinical study may have been too low. This dose was estimated to produce blood concen-
trations in the range of the 50% antiviral concentrations in cell culture, and was selected so as
to avoid any serious side effects.138 Thus, although bafilomycin A1 and chloroquine represent
excellent tools to examine the precise mechanism of influenza virus entry, their relevance for
influenza therapy is limited.
As explained in the next part, the adamantane compounds amantadine and rimantadine
block influenza A virus entry mainly by inhibiting the M2 proton channel. At higher (∼100
μM) concentrations, they raise the endosomal pH due to their basic character, thereby affecting
HA-mediated fusion at low pH.140 Hence, amantadine-resistant viruses selected in vitro can
contain mutations in either the M2 or HA protein. Most of these HA substitutions render the
HA less stable, and thus increase the pH at which fusion occurs. We recently observed that
some H1N1 viruses such as the A/PR/8/34 strain are particularly sensitive to a subtle increase
in the endosomal pH, as caused by newly synthesized amantadine analogues bearing different
scaffold structures (Torres, unpublished data).
5. INHIBITION OF THE VIRAL M2 PROTON CHANNEL
A. Structure of the M2 Ion Channel
The low pH inside the endosomes activates the viral M2 proton channel that is embedded in
the viral membrane, leading to transport of proton ions into the interior of the endosomally
entrapped virus. As a result, the vRNPs become dissociated from the M1 matrix protein (the
so-called “uncoating” event), and the viral genome is released.141
The M2 of influenza A virus (A/M2) is a short polypeptide of only 97 residues, assembled
into a homotetrameric, integralmembrane channel protein consisting of (i) a short unstructured
N-terminal ectodomain (residues 1–24); (ii) a pore-forming transmembrane helix (residues
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Figure 4. Solid-state NMR structure of amantadine-bound A/M2 proton channel in lipid bilayers. Side view
showing the luminal site. His37 and Trp41 function as pH sensor and gate, respectively, while Val27 acts as
a gatekeeper controlling the entrance of protons. The amantadine binding pocket is formed by Val27, Ala30,
Ser31, and Gly34. Substitution of these residues causes amantadine resistance. [Reprinted by permission from
Macmillan Publishers Ltd: Nature Ref. Cady et al.155 C© (2010).]
25–46) responsible for tetramerization andproton translocation; (iii) a cytoplasmic amphipathic
helix (residues 47–61), involved in virus assembly and budding; and (iv) a disordered tail
(residues 61–97) that interacts with the M1 matrix protein141 (Fig. 4). Activation of the M2 ion
channel belowpH6 is caused by protonation of the thirdHis37 residue in theM2 tetramer.142,143
The protonated imidazole ring of His37 is involved in a cation–π interaction with the indole
ring of Trp41.142 These two residues, His37 and Trp41, functioning as a pH sensor and gate,
respectively, are critical for M2 proton channel function, and hence invariable among influenza
A and B viruses.144,145 Besides, Val27 forms a valve that controls the entrance of protons,
while Asp44 is indirectly hydrogen bonded to the indole nitrogen of Trp41 via a water cluster
at the exit of the channel. Thus, Asp44 and Val27 act as gatekeepers at opposite ends of the
channel.146,147 Comparison of the NMR and crystal structures of the A/M2 transmembrane
domain obtained at neutral (pH 7.5–8), intermediate (pH 6.5), or acidic (pH 5) pH, provided
a detailed insight into the low pH-induced changes in A/M2 protein conformation.146–148 At
neutral pH, the Val27 valve is open, whereas the Trp basket, formed by the Trp41 residues
at the opposing end, has a small hydrophobic opening. When the pH is reduced, the Val27
valve constricts, while the Trp basket opens.147 Two mechanisms for proton transport through
the aqueous pore of A/M2 have been proposed. In the wire model, protons are conducted
via a continuous column of water molecules. Opening of the pore is achieved by electrostatic
repulsion of the protonated His37 residues, which, according to this model, play only a passive
role.142,149 In contrast, in the shuttle model, His37 plays an active role in proton transport
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Figure 5. Chemical structures of amantadine, rimantadine, and a selection of published analogues. The codes
shown are those used in the original reports. The spiro-adamantane compound 9161 possesses activity against
mutant A/M2 ion channels. The imine compound 8e166 and spiro compound 4b167 are both ∼200-fold more potent
than amantadine. Compounds 8168 and 24168 are ring-contracted and ring-expanded polycyclic analogues,
respectively.
by protonation and deprotonation, which is facilitated by imidazole ring reorientations and
small-amplitude backbone fluctuations.150,151
In analogy to the A/M2 protein, BM2 (the M2 protein from influenza B virus) forms a
homotetrameric integral membrane protein, with characteristic proton channel activity and a
pH profile similar to that of its functional homolog A/M2. Due to its coiled-coil structure, the
transmembrane region of BM2 is able to form a stable tetramer by itself, without the C-terminal
amphipathic helix that is necessary for tetramerization of A/M2.152 Except for the HXXXW
motif in the transmembrane domain, with the His and Trp acting as key residues for proton
channel activation and gating, A/M2 and BM2 share little sequence homology. Furthermore,
the BM2 proton channel activity is higher than that of A/M2.144 This higher conductance
may in part be explained by two extra serine residues in the channel pore of BM2, which can
facilitate proton relay.152
B. Inhibitors of the M2 Ion Channel
The discovery that the adamantane derivatives amantadine and rimantadine (Fig. 5) inhibit
influenza A virus replication was made decades ago153 and, in fact, was instrumental in eluci-
dating the function of M2.154 Both amantadine and rimantadine are inactive against influenza
B viruses. Cocrystallization of amantadine with the transmembrane domain of A/M2 identi-
fied a drug binding site in the N-terminal channel lumen, that is surrounded by residues that
are mutated in amantadine-resistant viruses (in particular, Val27, Ala30, Ser31, and Gly34).
Binding of amantadine apparently leads to occlusion of the channel pore, but may also affect
protonation of the critical His37 residue.146 On the other hand, a solution NMR of the A/M2
channel in complex with rimantadine revealed four equivalent binding sites, located on the
lipid-facing side of the channel, between adjacent helices near the Trp41 gate. In this way, bind-
ing of rimantadine could stabilize the closed state of the A/M2 tetramer.148 Finally, solid-state
NMR spectroscopy of A/M2 in phospholipid bilayers showed the existence of two amanta-
dine binding sites: a high-affinity site in the N-terminal lumen, which is occupied by a single
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amantadine molecule, and a low-affinity site at the C-terminal protein surface, which only
becomes occupied at higher amantadine concentrations.155 The presence of both binding sites
was confirmed by molecular dynamics simulations, which further indicated that amantadine
can bind inside the N-terminal lumen under low- and high-pH conditions.156 Importantly, the
identification of the A/M2 binding sites for amantadine and rimantadine provided an expla-
nation why both compounds lack activity against influenza B viruses. Compared to A/M2,
the BM2 pore has two more serine residues, which probably disable binding of the hydropho-
bic adamantane moiety within the BM2 channel.149,152 Also, the residues that make up the
low-affinity binding site for amantadine in A/M2 have uncorrelated counterparts in the BM2
protein.152
During many years, amantadine and rimantadine have been successfully used for both
prophylaxis and therapy of influenza A virus infections, though amantadine is associated with
neurological side effects.13 Nowadays, their clinical utility is limited sincemost circulating strains
are adamantane-resistant.157–159 Thirty percent of treated patients shed adamantane-resistant
mutants, which replicate equally well as wild-type virus, are cross-resistant to amantadine
and rimantadine, and are readily transmitted to contact persons.13,159 During the 2009–2010
season, 99.9% of H1N1 virus isolates were adamantane-resistant.157 The resistance mutations
are mostly located in the transmembrane region of the A/M2 protein, the most common
changes being Leu26Phe, Val27Ala, Ala30Thr, Ser31Asn, Gly34Glu, and Leu38Phe.160
Attempts were made to develop new adamantane derivatives, which are able to interfere
with the A/M2 ion channel activity of amantadine-resistant viruses. Guided by the novel
structural insights into the A/M2 binding interaction of amantadine, Wang et al. recently
developed spiro-adamantane inhibitors with potent activity against Val27Ala and Leu26Phe
mutantA/M2proteins.161 Thesemolecules have a larger size than amantadine and are therefore
able to fill the upper pore of A/M2, even when its volume is increased by the Val27Ala or
Leu26Phe substitution. One compound (9161; Fig. 5) showed antiviral activity against the wild
type as well as the A/M2-Val27Ala and A/M2-Leu26Phe mutant viruses, and its EC50 values
were similar to that of amantadine against the wild-type virus.161 An imidazole derivative of
pinanamine, synthesized by Zhao et al., showed moderate inhibition of an A/M2-Ser31Asn
mutant virus.162
Several research groups have developed polycyclic amine compounds to achieve more po-
tent inhibitors of A/M2.163–165 Two fine examples are the imine compound 8e166 (Fig. 5) and
the spiro compound 4b167 (Fig. 5), which were both reported to be ∼200-fold more potent
than amantadine. Although compound 8e166 was found to be cross-resistant to amantadine
when evaluated against an A/M2 mutant virus, it can serve as a novel scaffold for the design
of superior M2 blockers. Another study explored the size limits of polycyclic amine deriva-
tives as potential A/M2 inhibitors.168 Surprisingly, both ring-contracted (8168 in Fig. 5) and
ring-expanded (24168 in Fig. 5) polycyclic compounds were able to bind to wild-type A/M2,
and some analogues showed increased binding affinity compared to amantadine itself. Bio-
chemical studies with mutant A/M2 proteins and molecular docking indicated that compared
to amantadine, one of the ring-expanded derivatives showed a different binding mode to the
high-affinity A/M2 binding site (i.e., the inner channel pore region delineated by Val27, Ala30,
and Ser31).
Amantadine not only targets the A/M2 channel, but, as a weak base, also indirectly
inhibits HA-mediated fusion at concentrations at least 100-fold higher. Thus, an alternative
approach is to develop a compound reacting with both targets at similar concentrations. In
this case, viral resistance would require the appearance of amino acid changes in two separate
viral proteins, which may be expected to be a rare event. Replacement of the primary amino
group of amantadine by a more basic secondary or tertiary amino group, and addition of side
groups on the adamantane ring system, resulted in compounds interfering with HA at lower
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concentrations, while the concentration affecting M2 proton channel activity was increased.
However, during passage of the virus in the presence of these compounds, the escape ratewas still
high, yielding drug-resistant mutants with amino acid substitutions in both the HA and A/M2
proteins.169 A reason for this high escape rate may be that the resistance mutations selected by
these compounds can be located at different sites in HA or M2, without any reduction in viral
fitness.
6. HA-MEDIATED MEMBRANE FUSION: AN EMERGING ANTIVIRAL TARGET
A. Low pH-Induced Fusion Mechanism
The low pH inside the late endosome leads to an extensive and irreversible conformational
change of the viral HA, resulting in fusion of the viral and endosomal membranes (Fig. 2D). A
key role is played by the fusion peptide (defined as the 23 N-terminal residues of HA2), which is
themost conserved region ofHAand contains a series of hydrophobic residues.170,171 At neutral
pH, the fusion peptide is sequestered in a pocket of ionizable residues, but upon acidification, to
pH 5–6 for most influenza viruses, the fusion peptide is extruded toward the target membrane.
By comparing theX-ray crystallographic structures of the ectodomain portion ofHA, obtained
at either neutral or acidic pH, the following rearrangements were noted to occur at low pH: (i)
the globular head domain containing the RBS detrimerizes; (ii) the N-terminus of the central
triple-stranded coiled coil is extended by the interhelical chain and the short α-helix, hereby
releasing the fusion peptide from its buried position; and (iii) in the middle of the long α-
helix two turns undergo a helix-to-loop transition to form a 180◦ reverse turn, positioning
the fusion peptide and viral membrane anchor at the same end.55,172 The actual membrane
fusion proceeds through a hemifusion intermediate173 (Fig. 2D). According to the stalk-pore
model, the extruded fusion peptide inserts into the endosomal membrane. At the same time, the
C-terminus of HA2, which is anchored in the viral membrane, is reoriented thereby drawing
the endosomal and viral membranes together. After mixing of the outer membrane leaflets
(prefusion stalk intermediate), a hemifusion diaphragm is formed. Mixing of the inner and
outer membrane leaflets results in the formation of a fusion pore, allowing release of the
vRNPs into the cytoplasm.174
B. Inhibitors of HA-Mediated Membrane Fusion
1. Small Molecules Binding to the HA Stem
A first approach to interfere with the HA-mediated fusion process is to inhibit the acid-
induced conformational change of HA, using small molecules that bind to and stabilize the
neutral pH conformation. One of the first influenza virus fusion inhibitors to be reported
was tert-butyl hydroquinone (TBHQ; Fig. 6), which specifically inhibits H3 viruses.175 Several
years later, the binding site of TBHQ within the H3 HA stem structure was identified by
crystallization of the TBHQ-HA complex, and was shown to lie within a hydrophobic pocket,
formed at an interface betweenHA subunits.55 Besides several hydrophobic interactions, TBHQ
is hydrogen bonded with the side chain carbonyl of Glu572 and the main chain carbonyl of
Arg542 of one monomer, and the main chain carbonyl of Leu982 of another monomer, hereby
stabilizing the nonfusogenic HA conformation.55 During the conformational change of HA,
a critical role is played by the adjacent Lys582, located at the C-terminus of the short α-
helix and involved in the loop-to-helix transition.55 The relevance of the hydrophobic pocket
aroundGlu572 for the development of fusion inhibitors active against group 2 HAs was further
confirmed by our studies with the novel anti-influenza virus agent 4c (Fig. 6).176 Although
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Figure 6. Chemical structures of small-molecule inhibitors of the HA conformational change. For each com-
pound, the subtype specificity, as far as tested, is given in brackets. See the text for references on individual
compounds.
4c and TBHQ have very different chemical structures, we noticed a clear similarity between
the HA binding mode of TBHQ and that predicted for the N-(1-thia-4-azaspiro[4.5]decan-4-
yl)carboxamide part of 4c. However, the aromatic imidazo[2,1-b]thiazole ring of 4c allows the
formation of several additional hydrophobic interactions within this cavity. The inactivity of the
two compounds against group 1 viruses can be explained by analysis of HA crystal structures,
which revealed that residues 562–582 in group 1 HAs form an extra turn, resulting in blockage
of the TBHQ/4c binding site.55 Unfortunately, the antiviral activity of 4c is restricted to H3N2
viruses, since an H7N2 virus was shown to be insensitive, despite the fact that the H3 and H7
HAs belong to the same phylogenetic group 2. Also, resistance to 4c emerged within only three
passages in cell culture.176 Conversely, several fusion inhibitors targeting group 1 HAs have
been reported in the literature, that is, BMY-27709, CL-385319, RO5464466, and stachyflin
(see Fig. 6 for chemical structures), which inhibit the conformational change of H1 (and,
when tested, H2) HA but, unfortunately, have no activity against H3 viruses.177–180 Attempts to
override this subtype dependencyby synthesizing novel derivatives provedunsuccessful.181 Also,
initial predictions of their HA binding pocket using in silico docking did not fully correlate with
subsequent data obtained after cocrystallization of the compound with HA or photoaffinity
labeling.55,175,177,182 Whatever their virus specificity, these small molecule fusion inhibitors were
all found to readily select for resistance, at least in cell culture. Two types of resistancemutations
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have been identified. The first are amino acid substitutions within the binding pocket, which
affect the inhibitor binding to HA. Alternatively, the HA stabilizing effect of the inhibitors can
be counteracted by HA mutations that elevate the fusion pH, meaning that the mutant HA
acquires its fusogenic conformation at less acidic pH.55,176
Thus, further development of this type of small molecule fusion inhibitors has been hin-
dered by their subtype-dependent anti-influenza virus activities and low barrier for resistance
selection. There may, however, be other ways to inhibit the HA-mediated membrane fusion.
Instead of preventing HA refolding, diiodofluorescein induces the irreversible conformational
change of HA. These premature rearrangements, resulting in virions with fusion-inactive HAs,
also lead to inhibition of the fusion process.183
2. Antivirals Interfering with Membrane Fusion
Furthermore, it may be possible to interfere with membrane fusion following the HA refolding
event. This mode of action has been proposed for dextran sulfate, a sulfated polysaccharide
(Fig. 3) with broad-spectrum antiviral activity. This agent has been reported to inhibit not only
influenzaA virus, but alsoHIV,RSV,HSV, and cytomegalovirus.184–186 The anti-influenza virus
activity of dextran sulfate, which appears to be restricted to influenza A viruses, correlates with
its molecular weight, and levels off when the molecular weight increases above 10,000.184 The
anionic dextran sulfate can be assumed to form electrostatic interactions with the viral HA,
which has a net positive charge at pH7 or less.187 This is consistent with fluorescencemicroscopy
studies, showing the binding of fluorescein-labeled dextran sulfate to HA-expressing cells.188
While dextran sulfate had no effect on virus binding at 4◦C,184 it was found to inhibit the low
pH-induced fusion process using a fusion assay based on octadecyl-rhodamine fluorescence
dequenching.187 No direct inhibition of the acid-induced refolding of HA was noticed.188
However, in order to be active, the compound needed to be present during the fusion process
at low pH.187,188 These combined data suggest that the dextran sulfate binding site might be
inaccessible in the low-pH HA-membrane complex and that dextran sulfate may interfere with
a step subsequent to the conformational rearrangement of HA, for instance by causing steric
hindrance of the membrane mixing event.188,189 It remains to be investigated whether other
polysulfated polysaccharides with anti-influenza virus activity (such as compound pKG-03
that was isolated from a microalga190) have a similar mode of action as dextran sulfate.
Another high molecular weight molecule, retrocyclin 2, also acts against a wide range
of viruses, including influenza virus, HIV, and HSV.191–194 Retrocyclin 2 is a circular octade-
capeptide belonging to the θ -defensins, which are antimicrobial peptides of the innate immune
system.195 A detailed mechanistic study showed that its inhibitory effect on influenza virus
replication was based on prevention of the HA-mediated membrane fusion at low pH.194 How-
ever, retrocyclin 2 remained effective when added after the conversion of HA to its fusogenic
conformation or after hemifusion, an intermediate state in which the outer membrane leaflets
have merged while the inner leaflets are still separated. Thus, retrocyclin 2 was proposed to pre-
vent the subsequent membrane rearrangements by causing cross-linking and immobilization
of surface glycoproteins.194
A similar interference with the membrane fusion process probably accounts for the broad
anti-influenza virus activity of arbidol. This small molecule (Fig. 3) has been licensed in Russia
and China for influenza virus prophylaxis and therapy. Besides influenza A and B viruses,
its antiviral spectrum encompasses RSV, parainfluenza virus, rhinovirus, hepatitis B virus,
and HCV.196 It is well tolerated as a drug and arbidol-resistant influenza viruses have not
(yet) been isolated in the clinic.197 However, arbidol-resistant viruses, obtained after 14 virus
passages in cell culture, were shown to carry mutations in the HA2 subunit associated with
an increased fusion pH.197 Arbidol may thus act by stabilizing the prefusogenic HA protein
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in a similar manner as TBHQ and the other small molecule fusion inhibitors described above,
but, unlike the latter compounds, arbidol is less subtype-specific.197 An alternative mode of
action was proposed from biochemical studies with various model membranes, showing that
arbidol has membranotropic properties, particularly due to its interaction with negatively
charged membrane phospholipids.198,199 Since this membrane interaction is most pronounced
at acidic (fusion) pH, arbidol could alter the membrane fluidity during the fusion process
and make the bilayer less fusogenic.196 Likewise, the inhibitory effect of arbidol toward HCV
entry was explained by its capacity to dually interact with cell membrane phospholipids and
aromatic residues (such as tryptophan) that are present in fusion-mediating glycoproteins of
HCV. This complexation would prevent the conformational changes in the viral glycoprotein
required for membrane fusion.196,198 At this time, a dual interaction of arbidol with membrane
phospholipids and the influenza virus HA is merely speculative, but this mode of action would
reconcile the biochemical and virological in vitro data outlined above. In the context of in
vivo studies, arbidol may also have immunostimulatory properties by inducing interferon-α,
activating phagocytic macrophages, or stimulating the humoral and cell-mediated immune
response.200
3. Broad-Neutralizing Antibodies
As already explained, several reported fusion inhibitors suffer from subtype-dependent anti-
influenza virus activity and rapid emergence of resistance. These drawbacks could be avoided
by targeting the fusion peptide, which is highly conserved among all HAs and contains the
23 N-terminal residues of HA2. A monoclonal antibody directed against the first 15 residues
of HA2 was selected from mice immunized with an H5N1 virus.201 In vitro, this MAb 1C9
antibody inhibits syncytium formation in HA-expressing cells, indicating inhibition of the
fusion process. When administered to mice, MAb 1C9 provided protection against H5N1, both
prophylactically and therapeutically.201 Though highly relevant, cross-reactivitywith otherHAs
was not yet investigated.
A recent strategywith high clinical relevance comes from thediscovery of broadneutralizing
antibodies directed against relatively conserved pockets in the HA stem structure.202 Already
in 1993, the first antibody reacting with different HA subtypes was selected.203 This mouse
monoclonal antibody, designated C179, was shown to neutralize the H1, H2, and H5 HAs,
all belonging to group 1.203,204 Identification of the resistance mutations in C179-resistant
viruses, obtained by virus passaging in the presence of this antibody, allowed to locate its
binding site in the middle of the HA stem. C179 was proven to inhibit HA-mediated fusion in
a polykaryon assay in influenza virus-infected cells,203 and was shown to be effective in H1N1-
or H2N2-infected mice.205 The first human antibodies to be identified were specific for either
group 1 or group 2 HAs, and were obtained by systematic screening of a wide array of B-cells
from influenza-vaccinated or influenza-infected individuals, or by constructing combinatorial
libraries. The antibodies F10 and CR6261 show broad neutralizing activity against group 1
HAs, and a partially overlapping binding pocket within the HA stem.206–208 Crystallization of
F10 and CR6261 in complex with H1 or H5 HA revealed that a conserved hydrophobic tip
on their HCDR2 region inserts into a hydrophobic pocket adjacent to the short α-helix in the
HA stem, thereby allowing interactions of the antibody with the fusion peptide.206,207 Another
monoclonal antibody, encodedCR8020, interacts with H3 andH7HAs, which belong to group
2. Cocrystallization of CR8020 with H3 HA identified its binding pocket lower down the HA
stalk, thus in closer proximity to the viral membrane compared to CR6261.209 Stabilization of
the HA prefusogenic conformation by CR6261 and CR8020 was corroborated by the finding
that both antibodies prevented exposure of protease-susceptible sites in HAwhen the virus was
incubated at low pH.206,209
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Broad coverage of all influenza A viruses could be achieved by combining a group 1 and
group 2 specific antibody. Further significant progress wasmade byCorti et al., who successfully
isolated a pan-influenzaAneutralizing antibody that recognizes all group 1 and group 2HAs, by
interrogating a large number (about 100,000) of donor plasma cells.210 Cocrystallization of this
FI6 antibody with an H1 or H3 HA protein revealed its interaction with a conserved epitope in
the F (fusion) subdomain.210 Hence, binding of FI6 or the optimized FI6v3 antibody is assumed
to increase the stability of the F subdomain, thus preventing the conformational change of HA
that is required for membrane fusion. This mode of action accords with the inhibitory effect
of FI6 on syncytium formation in HA-positive cells. Alternatively, prevention of HA0 cleavage
(at least for viruses requiring extracellular cleavage) or cross-linking of HA subunits, have been
implicated in the virus-neutralizing activity of FI6. Passive immunization with FI6 was shown
to confer prophylactic and therapeutic protection to influenza virus-infectedmice and ferrets.210
Recently, Dreyfus et al. isolated the human monoclonal antibody CR9114, which neutralizes
influenza A and B viruses.86 CR9114 recognizes an epitope in the HA stem that is nearly
identical to that of the group 1-specific antibody CR6261. However, subtle conformational
differences explain why the CR9114 antibody has a much broader anti-HA reactivity.
Another HA stem-binding antibody,PN-SIA28, showed antiviral activity against all group
1 viruses tested (i.e., H1N1, H2N2, H5N1, and H9N2 viruses), as well as some isolates of the
H3N2 virus, which belongs to group 2.211 However, H3N2 strains isolated after 1982 and
H7N2 viruses were not inhibited. In order to localize the binding epitope for PN-SIA28 in
the HA stem, the authors selected escape mutants by repeated passaging of the virus in the
presence of the antibody. Similar attempts to generate escape mutants with some of the other
broad neutralizing antibodies suggest that viruses with mutations in the corresponding HA
stem regions do not readily emerge in cell culture. For instance, with the CR6261 antibody,
ten virus passages were required,208 while in other studies, no escape mutants were detected.212
These observations seem to indicate that the conserved HA stem epitopes targeted by these
broad acting antibodies are less prone to mutations due to fitness constraints. This hypothesis,
however, still remains to be verified by mutational analysis. It is clear that the discovery of
these broad neutralizing anti-HA stem antibodies offers entirely new perspectives for passive or
active immunization against influenza A viruses. Also, peptides directed against the conserved
epitopes in the HA stem region have been developed, such as the HB36 peptide that interacts
with the CR6261-binding epitope and recognizes several group 1 HAs (i.e., H1, H2, H5, and
H6).213 The concept of a therapeutic peptide used to inhibit virus fusion is validated in the
HIV field by the clinical use of enfuvirtide, a 36 amino acid peptide that binds to the HIV gp41
protein.214
7. INHIBITION OF NP-MEDIATED VIRAL NUCLEAR IMPORT
After disruption of the vRNPs from the matrix M1 protein and fusion pore formation, the
vRNPs are released in the cytoplasm and transported into the nucleus.215,216 How the vRNPs
are released fromM1 is only partially understood. In the intact virion, theM1 protein forms the
capsid shell locatedunderneath the envelope, and is tightly associatedwith the vRNPs.217,218 The
current insights into the protein structure ofM1and its crucial role in organizing virion structure
were recently reviewed.219 Once inside the endosome, theM2-mediated acidificationof the virion
interior leads to vRNP uncoating, possibly by inducing a conformational change in M1.220,221
Recent studies indicate that the oligomerization state ofM1 is pH-dependent and that oligomers
of intact M1 dissociate into stable dimers at acidic pH.222 The disappearance of a visible
M1 layer in virions exposed to pH 5 was imaged by cryoelectron tomography.223 After their
transport through the fusion pore, the vRNPs appear to be associated with some residual M1
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Figure 7. Chemical structure and NP-binding site of nucleozin. (A) Chemical structure of nucleozin (R = H),236
3061 (R = Cl),238 and compound 3 (R = OMe).239 (B) X-ray structure of the oligomeric complex of compound 3
with influenza virus NP. Six molecules of compound 3 bridge two NP trimers (NP trimer A and NP trimer B) to form
a hexamer. [Taken from Gerritz et al.,239 with permission.] Critical interactions made by compound 3 include a
hydrogen bond with Ser376 and a π -stacking interaction with Tyr289.
protein, which, inside the cytoplasm, dissociates from the vRNPs to finally allow their nuclear
entry.215,224 This second dissociation process may depend on cytosolic M1 modifications, such
as phosphorylation or zinc binding.220,225 A peptide derived from the zinc finger domain of
M1 was reported to display broad and potent anti-influenza virus activity in cell culture when
added within 1 hr after infection, classifying this “peptide 6” as an entry inhibitor.226 As far as
we know, no other attempts have been reported in whichM1was explored as an antiviral target.
Development of a potent M1 inhibitor might be challenging, due to the abundant presence of
this protein in the virion.
At last, the free vRNPs are imported in the nucleus via the nuclear pores. Each vRNP
contains one of the eight vRNA genome segments, which is associated with a single copy of the
viral polymerase (the heterotrimer of PB1, PB2, and PA), and multiple copies of the nucleo-
protein (NP).227 Although these four viral proteins all contain at least one nuclear localization
signal (NLS), the vRNP nuclear import appears to be primarily dependent on the NLS in the
N-terminus of NP.228–230 Due to this NLS, the vRNP is recognized as a cargo by the cellular
importin-α protein, and after formation of a ternary complex with importin-β, is transported
into the nucleus.231 The specificity of NP (and PB2) for the different isoforms of importin-α
differs for avian and human viruses, implicating a role in influenza virus adaptation.231,232
The viral NP has both structural and regulatory functions in influenza virus replication.
Besides being the main structural component of the vRNPs, NP has a crucial role in the
consecutive replicative stages, by regulating vRNP nuclear import; viral RNA transcription;
and nuclear export (via interaction of NP with M1).233 The conserved protein sequence of NP
further adds to its attractiveness as an antiviral target, since this implicates that NP inhibitors
could be broadly active across the different virus subtypes.233 This is illustrated by the small
molecule ingavirin, which inhibits influenza A and B viruses in vitro and in vivo.234 Ingavirin
was reported to inhibitNPoligomerization and subsequent nuclear import of newly synthesized
NP.235 This mechanism of action is distinct from that of the NP aggregating agents nucleozin
and its structural analogues 3061 and “compound 3”, which were independently identified by
several groups236–239 (Fig. 7A).
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These NP binding agents display anti-influenza virus activity against all influenza A viruses
tested, including H1N1, H3N2, and H5N1 viruses.238,239 In the first report, nucleozin was
proven, by fluorescence microscopy, to cause NP aggregation and trap the vRNPs in a peri-
nuclear halo.236 Nucleozin was also active in the cellular vRNP reconstitution assay, which
directly measures the transcriptional activity of vRNP.236 This indicates that nucleozin not
only interferes with nuclear entry, but also with other replicative processes in which NP is
involved. The NP aggregating activity of nucleozin was confirmed by experiments in which NP
was cocrystallized with the related “compound 3”.239 Formation of higher order NP oligomers
was observed, in which two NP trimers are linked to each other through six molecules of
“compound 3”, each interacting with two antiparallel binding pockets.239 The nitrophenyl
moiety of “compound 3” interacts with one binding pocket (close to the NP residues Tyr289
andAsn309) in anNP fromone trimer,while the isoxazole heterocycle binds to the other binding
pocket (around theTyr52 residue) of anNP in the other trimer, and vice versa239 (Fig. 7B). These
data nicely agree with the resistance mutations identified in NP (i.e., Tyr52Cys/His, Tyr289His,
and Asn309Lys) after virus passaging in the presence of these NP binding agents.236,238,239
Nucleozin showed a rather modest in vivo activity, protecting 50% of H5N1-infected mice.236
However, full protection of H5N1-infected mice was obtained with “compound 5”, a derivative
of “compound 3” with improved solubility and metabolic stability.239
8. INTERFERING WITH CELLULAR FACTORS INVOLVED IN INFLUENZA VIRUS
ENTRY
Although most available antiviral strategies are directed toward a viral protein, the possibi-
lity to block a cellular component with a critical role in virus replication receives increasing
attention.240 An antiviral targeting a host cell factor can be assumed to have reduced selectivity
(i.e., window between cytotoxicity and antiviral efficacy). On the other hand, its resistance
barrier could (in theory) be higher when compared to a direct antiviral compound.241 For a
virus with a highmutation rate such as influenza virus, this appears a considerable advantage.242
Two studies using genome-wide RNA interference screening identified several host cell
factors necessary for influenza virus replication.135,243 Further analyses, based on apseudotyped
particle entry assay, allowed the selection of cellular factors that regulate the low pH-dependent
and HA-mediated entry. Among them are proteins involved in the IP3-protein kinase C (PKC)
or phosphatidylinositol-3-kinase (PI3K)-Akt signaling pathways; COPI components (involved
in endosomal trafficking); vacuolar ATPases; fibroblast growth factor receptor135; and SON
DNA binding protein (important for influenza virus trafficking to late endosomes).243 These
intriguing data create new opportunities for designing antiviral concepts toward host cell
factors.242 In a proof-of-concept study, compounds such as sirolimus, podophyllotoxin, or
other inhibitors of any of these host cell factors, were found to inhibit virus replication with
quite remarkable selectivity.135
The bisindolylmaleimide compounds specifically inhibit all PKC isoenzymes with a similar
potency, by blocking the ATP-binding site on the catalytic domain of PKC.244 Bisindolyl-
maleimide I has been shown to interfere with influenza A and B virus replication early in
infection, probably by affecting endocytosis or vesicle transport.245 The PKCβII isoform was
proven to be critical for influenza virus entry, since accumulation of the virus in late endosomes
was observed in cells expressing a phosphorylation-deficient form of PKCβII.246
The PI3K and its downstream effector Akt/protein kinase B are signaling mediators
induced by influenza A virus, and their role in virus replication seems to be multifaceted.247
Upon virus attachment to the cell, PI3K is activated in a short and transient manner, promoting
a step during virus entry that precedes early and late endosomal transport.123,247 At later
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stages of infection, the influenza A virus nonstructural NS1 protein induces a second phase
of sustained PI3K activation to prevent premature apoptosis during viral propagation. The
influenza B virus NS1 protein apparently lacks this function.248 In contrast, accumulation
of vRNA leads to PI3K activation in cells infected with influenza A or B viruses. Finally,
PI3K signaling is also essential for efficient IRF-3 activation during type I interferon (IFN)
induction.249 The antiviral effect of IFN is mediated by the interferon inducible transmembrane
(IFITM) protein 3 and results in inhibition of viral genome release into the cytoplasm.250
Notwithstanding this complex function of PI3K, it was shown that inhibition of PI3K results
in decreased influenza virus replication,247 which makes this pathway a potential antiviral
target.
9. PERSPECTIVES
During the past years, significant advances have been made in unraveling the structure of the
influenza virus proteins involved in virus entry, from its initial attachment to the sialylated
receptors until its nuclear entry. The available crystal structures of HA, M2, and NP enable
a rational and computer-aided design of directly acting antivirals. A few M2 inhibitors with
activity against amantadine-resistant viruses have already been reported. The old paradigm
that the HA appears too variable to be a valid antiviral target is challenged by broad-acting
macromolecule inhibitors, such as lectins or antibodies interacting with a conserved site in the
HARBS or stem region.Whereas small molecules inhibiting the conformational change of HA
have a restricting subtype dependency, this is not the case for compounds (such as arbidol),
which interfere with the membrane fusion event itself. The recently discovered NP aggregating
agent nucleozin represents an entirely novel class of anti-influenza agents with clinical relevance.
Complementary to these structural studies,much attention is currently given to the complex
cell biology of the influenza virus entry pathway, with a particular interest in the host cell factors
involved. Diverse compounds interfering with any of these cellular factors have been reported,
setting the stage for a new type of indirectly acting antivirals with a higher barrier for resistance
selection. In times of increasing resistance to oseltamivir, agents with amore favorable resistance
profile are indeed urgently required.
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